Table 4 Pim kinase inhibitors used in preclinical and clinical (bold) trials for ALL
From: Targeting Pim kinases in hematological cancers: molecular and clinical review
Acute Lymphoblastic Leukemia | Target | Type | Clinical Trials |
|---|---|---|---|
AZD1208 | pan-Pim | Single | Yes |
AZD1208 + Ponatinib or Dasatinib | pan-Pim + TKI | Dual-therapy | – |
AZD1208 + Ponatinib + Z-VAD-FMK | pan-Pim + TKI+ pan-caspase | Triple-therapy | – |
AZD1208 + Sabutoclax | pan-Pim + BCL2 | Dual-therapy | – |
AZD1208 + inLCK | pan-Pim + LCK | Dual-therapy | – |
LGB321 | pan-Pim | Single | Preclinical |
PIM447 | Pan-Pim | Single | Yes |
Smi-4a | Pim1 | Single | Preclinical |
Smi-4a + U0126 | pan-Pim + MEK1/2 | Dual | – |
TP-3654 | Pan-Pim | Single | Preclinical |
TP-3654 and dexamethasone | Pan-Pim and glucocorticoid therapy | Dual-therapy | – |